Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines. 

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.

Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Originally intended to increase medical device safety, the EU’s medtech regulation is so hampered in its implementation that it is now arguably a bigger potential threat to patients than any of the scandals leading to its more stringent requirements.

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.

Originally intended to increase medical device safety, the EU’s medtech regulation is so hampered in its implementation that it is now arguably a bigger potential threat to patients than any of the scandals leading to its more stringent requirements.

From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.

A selection of articles you might have missed from November 2022, during which In Vivo shone the spotlight on the Asia Pacific region.